Flucofarma

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucofarma

Quick Facts about Flucofarma

Property Description
Active Ingredient Fluconazole
Forms Tablet, Capsule, Oral Suspension, IV Solution
Pharmacological Class Triazole Antifungal (Azole Class)
Common Use Treating Fungal and Yeast Infections
Origin Synthetic (First-Generation Triazole)

What Type of Medicine is Flucofarma (Fluconazole)?

Flucofarma is a systemically acting pharmaceutical preparation that contains the active ingredient fluconazole, which is classified as a triazole antifungal agent. This compound is synthetic, belonging to the broader azole class of medications developed to combat pathogenic organisms such as fungi and yeasts. Fluconazole is clinically recognized for its favorable pharmacokinetic profile, allowing for predictable absorption and distribution throughout the body. This first-generation triazole is approved for a wide range of patient groups, including specific use in children, a differentiating factor supported by extensive pharmacological studies.

Composition and Available Forms of Flucofarma

The medication is a single-component product, containing only the active agent fluconazole alongside necessary inactive ingredients. Flucofarma is presented in multiple dosage forms, a feature essential for comprehensive care: solid forms like the tablet and capsule for oral administration, an oral suspension for liquid intake—often preferred for pediatric patients—and a sterile solution for intravenous infusion. The versatility in forms, particularly the ready-to-use intravenous option, allows medical professionals to initiate therapy promptly even when oral intake is compromised.

General Purpose: What Flucofarma Does Against Fungal Infections

The core therapeutic purpose of Flucofarma is to control the growth and spread of susceptible fungal infections and yeast infections internally. Fluconazole achieves this by interfering with the fungus's ability to create ergosterol, an essential component of its cell structure. This mechanism, which induces fungistatic activity, is pharmacologically proven to halt the organism's proliferation. For instance, the medicine is typically used when a patient develops an infection in the mouth or throat, which requires a systemic agent to resolve the underlying fungal colonization.

Regulatory References

  1. WHO Model List of Essential Medicines, Fluconazole

What side effects are possible with Flucofarma?

Possible Side Effects and Safety Information

The safety profile of Flucofarma (fluconazole) is documented in official regulatory sources, which classify possible adverse reactions according to frequency and the body system affected. These classifications establish the risk characteristics without providing instructions for clinical use.

Frequency-Classified Adverse Reactions

The most frequently documented side effects, officially classified as Common (affecting ge 1 in 100 people), typically involve the gastrointestinal system and the nervous system. These commonly include headache, nausea, vomiting, diarrhoea, and abdominal pain, alongside elevations in specific liver enzymes (ALT, AST, ALP).

Reactions classified as Uncommon (affecting ge 1 in 1,000 people) may include insomnia, dizziness, pruritus (itching), urticaria, and anaemia.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the occurrence of rare but serious adverse reactions across several system-organ classes. These serious reactions include:

  • Severe Hepatic Toxicity (e.g., hepatic failure, hepatocellular necrosis).
  • Severe Cutaneous Reactions (e.g., Stevens-Johnson syndrome, Toxic epidermal necrolysis).
  • Cardiac Events (e.g., Torsade de pointes, QT interval prolongation).

Safety statements indicate the medicine is contraindicated in individuals with known hypersensitivity to fluconazole or related azole substances. Caution is advised for patients with pre-existing risk factors for cardiac arrhythmias, such as specific heart diseases or electrolyte disturbances (like hypokalemia). For patients with hepatic impairment, close monitoring of liver function is documented as necessary during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based solely on official regulatory documents and describes the signs and required actions associated with an overdose of Flucofarma (fluconazole).

Documented Manifestations of Overdose

Official prescribing information documents that high exposure has been associated with specific changes in mental status.

Overdose Presentation Detail
Mental Status Changes Includes hallucination and paranoid behavior.

Required Emergency Action

Immediate medical attention is necessary following a suspected or known overdose, as specialized medical support is required. This urgency is emphasized due to the lack of a specific pharmacological antidote for fluconazole.

Management and Supportive Measures

Professional medical management of overdose focuses on supportive care and the potential for enhanced drug elimination. Regulatory guidance indicates that management involves general symptomatic treatment and necessary supportive measures.

  • Procedural Intervention: Gastric lavage may be considered appropriate by medical staff.
  • Enhanced Elimination: Since Flucofarma is largely excreted unchanged in the urine, hemodialysis can be used. A three-hour session of hemodialysis is documented to reduce the body's plasma concentration of fluconazole by approximately fifty percent.

Therapeutic Uses of Flucofarma

What Flucofarma Treats: Main Uses and Benefits

Flucofarma (fluconazole) is an oral and systemic antifungal treatment commonly used to help manage various conditions caused by fungal and yeast organisms. The medication plays a role in managing infections across critical therapeutic domains, providing the core therapeutic benefit of addressing the underlying cause of infection and easing associated distress.

This medication is applied across domains where additional symptomatic support is needed. It is relevant in conditions presenting with systemic or localized discomfort, assisting with maintaining functional stability.

Key Therapeutic Applications

Flucofarma is used for managing conditions such as oral thrush, esophageal candidiasis, vaginal candidiasis (thrush in women), candidemia (yeast in the blood), and cryptococcal meningitis. It is also applied in clinical settings to manage the risk of developing new fungal infections or to support the prevention of recurrent manifestations in immunocompromised patients.

This medication helps address symptom clusters related to soreness, redness, and inflammation in the mouth, throat, and genital areas. It is commonly used when symptoms intensify, providing supportive relief that helps patients cope more steadily with difficult episodes.

“The medication is applied in therapeutic areas where supportive symptom management is appropriate for serious or recurrent fungal infections.”

Quick Fact: Relief for Mucosal Discomfort
Symptom Category Symptoms related to inflammatory or irritative states (e.g., oral or genital soreness).
Clinical Scenario Used during phases when symptoms become more noticeable and may interfere with daily functioning.
Primary Benefit Contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Flucofarma? — Official Regulatory Information

The eligibility for Flucofarma (Fluconazole) is defined by official regulatory documentation, establishing both absolute exclusions and conditional use requirements.


Eligibility Scope

Classification Eligibility Rule (Based on Regulatory Labeling)
Populations for whom use is allowed Adults and children (pediatric use is established for many indications, with dosing adjusted by age and weight). Older adults without evidence of severe renal impairment.
Populations for whom use is contraindicated Individuals with known hypersensitivity to fluconazole or other azole derivatives. Patients concurrently taking specific medications known to prolong the QT interval and metabolized by the CYP3A4 enzyme (e.g., pimozide, quinidine).
Populations for whom use is restricted Patients with Renal Impairment must receive a reduced maintenance dose (e.g., 50% for Creatinine Clearance le 50 mL/min). Patients with Hepatic Impairment require close monitoring.
Pregnancy and Lactation Eligibility Pregnancy: Generally not recommended. High-dose (400–800 mg/day) and/or long-term use is associated with a risk of birth defects and is often contraindicated except for life-threatening infections. Lactation: Use is not recommended for repeated or high-dose therapy.
Age-Related Rules Eligibility is established for pediatric use, but specific indications (like single-dose vaginal candidiasis) may be not recommended for children under 16. Geriatric patients require renal function assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flucofarma (Fluconazole) is classified as a potent inhibitor of the cytochrome P450 (CYP) isoenzymes CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This mechanism can lead to significantly increased blood levels of numerous co-administered medicinal products that are metabolized by these enzymes, raising the risk of toxicity. The inhibitory effect on these enzymes may persist for four to five days after stopping Flucofarma due to its long half-life.

Contraindicated Combinations

Co-administration is strictly contraindicated with several medicinal products due to the risk of serious cardiotoxicity, including QT interval prolongation and torsades de pointes. This includes astemizole, cisapride, pimozide, quinidine, and erythromycin, as well as high-dose terfenadine.

Significant Interactions Requiring Caution

Category Examples of Interacting Medicines Interaction Result/Action Required
Anticoagulants Warfarin Increased risk of bleeding; necessitates careful monitoring of prothrombin time/INR.
HMG-CoA Reductase Inhibitors (Statins) Atorvastatin, Simvastatin Increased risk of myopathy and rhabdomyolysis; requires dose adjustment/monitoring.
Oral Hypoglycemics Glipizide, Glyburide Increased risk of hypoglycemia (low blood sugar); requires blood glucose monitoring and potential dose reduction.
Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus Significantly increased plasma concentrations; requires frequent monitoring and dose reduction.
Rifamycins Rifampicin Rifampicin decreases Flucofarma exposure; a Flucofarma dose increase may be considered.

Close monitoring and potential dose adjustments are also required for numerous other agents, including certain anti-epileptics (e.g., phenytoin), NSAIDs (e.g., celecoxib), and certain antidepressants.

Mechanism of Action

Specific Inhibition of Fungal Ergosterol Biosynthesis

Flucofarma's core mechanism is the highly selective inhibition of lanosterol 14-alpha demethylase (14α-demethylase), a fungal-specific enzyme essential for cell structure. The molecule blocks this enzyme, halting the conversion of lanosterol and preventing the production of ergosterol, the primary lipid component required for the pathogen's cell membrane. This targeted molecular interference dictates the resulting physiological consequence.


Disrupting Cell Membrane Integrity and Function

The molecular blockade leads to a cascade where abnormal, toxic sterols accumulate in place of ergosterol, compromising structural and functional defects in the fungal cell membrane. This damage compromises the organism's ability to maintain homeostasis, absorb nutrients, and divide, establishing fungistatic activity (the mechanism of growth cessation).


Constraints on Mechanistic Efficacy

The drug's mechanism is constrained by biological factors such as acquired fungal resistance, which can manifest through two main avenues: genetic mutation of the target enzyme (reducing affinity) or the overexpression of efflux pumps that rapidly push the fluconazole molecule out of the fungal cell. This limits the drug's capacity to sustain the required inhibitory concentration at the enzyme target site.

Dosage and Administration Information

Official Administration Guidelines

The use of Flucofarma (fluconazole) follows specific dosage and administration instructions, which vary based on the specific infection being treated and patient factors. It is available for Oral administration as capsules or oral suspension, and for Intravenous (IV) infusion.

Capsules should be swallowed whole, and the oral suspension should be shaken well before use. Flucofarma may be taken with or without food. The medication is typically administered once daily (qDay), though some indications, like vaginal candidiasis, are treated with a single 150 mg oral dose.

Dosing and Special Conditions

For most multiple-dose regimens, a loading dose of twice the usual daily dose is recommended on the first day to help achieve steady-state plasma concentrations more rapidly.

Age Group Key Administration Rule
Adults Daily dose range is typically 50 mg to 400 mg.
Children Dosing is based on body weight (mg/kg), and the maximum adult daily dose must not be exceeded.
Neonates Dosing intervals are extended (e.g., every 72 hours for the first 2 weeks of life) due to immature renal function.

For patients receiving multiple doses who have renal impairment (Creatinine Clearance ≤ 50 mL/min), the dose must be reduced after the initial loading dose. Patients on regular dialysis should receive 100% of the recommended dose after each session. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped; do not double the dose to make up for a missed one.

Treatment must be continued for the duration prescribed by the healthcare professional, even if symptoms improve, as duration is based on the clinical and mycological response to the infection.

Recent Clinical Evidence

Flucofarma: Recent Clinical Evidence

Efficacy and Clinical Endpoints

Studies have explored whether the drug is associated with changes in pre-defined clinical endpoints in people with Condition A. These evaluations typically focused on a change in a primary symptom score over a 12-week period.

  • Primary Symptom Change: Data from Phase 3 studies indicated that the pre-defined primary endpoint was the observed change in the symptom score recorded for participants receiving the drug.
  • Duration of Observed Effects: Studies evaluated the onset of changes and the duration of observed effects on symptoms. The median time to a detectable change was measured, but findings varied across the trials.

Early research included an evaluation of inflammation markers. The study designs involved measurement of Marker X and Marker Y at predetermined intervals, with protocols defining the endpoint as the change in these markers after four weeks of administration.


Combination Studies

Research examined whether a combination of Drug Y and Drug Z was associated with changes in the overall frequency of episodes. These studies involved participants who were already stable on Drug Z before the experimental addition of Drug Y.

Outcome Measure Study Type
Frequency of Episodes (per month) Monotherapy vs. Combination
Comparison to Traditional Therapies Participants with Mild Symptoms

Safety Profile and Administration Research

Research protocols documented the use of a range of starting doses and the collection of data on the occurrence of side effects. Research has also investigated whether taking the dose with a meal influenced absorption. One trial measured the drug's concentration in plasma following administration with and without food.

Clinical trials evaluated outcomes in participants, including those with pre-existing conditions such as a history of kidney issues. Protocols included monitoring for specific adverse events throughout the duration of the trials.

Key Studies & References

  1. Fluconazole Tablets Product Monograph (Health Canada/Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Flucofarma (FAQ)


Q: What is Flucofarma used for besides yeast infections?

Flucofarma is indicated for the treatment of several systemic fungal and yeast infections beyond common ones. These include specific conditions like cryptococcal meningitis, esophageal candidiasis, and peritonitis. Official documentation also indicates its use for the prevention of candidiasis in certain high-risk patient populations, such as those undergoing bone marrow transplants.


Q: Does Flucofarma treat all different kinds of fungal infections?

Flucofarma is a triazole antifungal and is described as targeting specific fungal species that are susceptible to it. Regulatory documents list the infections it is approved to treat, which include various forms of candidiasis. Official reports acknowledge that the drug is not effective against all fungal species, and resistance mechanisms have been reported for some strains.


Q: Is it normal for Flucofarma to not work immediately after the first dose?

Research indicates that the full effect is typically not immediate, as the drug's mechanism works by halting the growth of the fungus. For infections like vaginal candidiasis, symptoms generally begin to improve within a day, but the drug continues to act in the body. The full resolution of symptoms often takes a longer period.


Q: Why is Flucofarma sometimes prescribed as a single dose?

The drug is approved and often administered as a single dose, specifically for the treatment of vaginal candidiasis (a vaginal yeast infection). This is possible because Flucofarma has a favorable pharmacokinetic profile, allowing for extended exposure to the active substance after one administration.


Q: Can Flucofarma interfere with or change the effectiveness of birth control pills?

Official information indicates that Flucofarma may alter the blood levels of the hormones ethinyl estradiol and norethindrone, common ingredients in oral contraceptives. Regulatory guidance describes the need for monitoring for side effects, such as unusual nausea or vaginal bleeding, when these medications are taken together.


Q: Is it acceptable to drink alcohol in moderation while taking Flucofarma?

Some official patient guides state that drinking alcohol while taking fluconazole is permissible. However, due to the drug's potential for liver-related side effects, official sources indicate that alcohol consumption may contribute to the risk of liver damage or intensify common side effects. Patients should consider the liver-related safety constraints described in the drug's label.


Q: Are there any food or drinks that should be completely avoided when using Flucofarma?

The FDA-approved label explicitly states that Flucofarma can be taken with or without food because its absorption is not affected by food consumption. There are no specific foods or non-alcoholic drinks listed for required avoidance.


Q: Does Flucofarma cause changes in taste or a metallic taste?

Official summaries of common side effects report that Flucofarma can cause a change in the way food tastes or, in some cases, a loss of taste entirely.


Q: Does Flucofarma cause hair loss or changes in skin color?

Hair loss (alopecia) and changes in skin color are among the documented adverse events. According to post-marketing surveillance reports, these effects are more often associated with long-term treatment.


Q: Can Flucofarma cause problems with the adrenal glands?

Official warnings mention that adrenal insufficiency (a problem with the adrenal gland) has been reported in patients taking azole antifungals, including fluconazole. These reports often describe the condition as reversible after stopping the drug.


Q: How long does Flucofarma stay in the body after the last pill is taken?

Flucofarma has a long elimination half-life of approximately 30 hours in individuals with normal kidney function. The elimination of half of the drug from the body typically occurs over approximately 30 hours.


Q: Does the drug have a warning for people with low blood potassium or magnesium levels?

Regulatory documents indicate that caution is advised for patients with pre-existing electrolyte abnormalities, such as low blood levels of potassium (hypokalemia) and magnesium. These conditions are cited as increasing the risk of serious heart rhythm problems associated with the drug.


Q: Is the medication a concern for people with lactose or specific sugar intolerances?

Official labels list all inactive ingredients (excipients) for the specific formulation being used. Since inactive ingredients can vary by manufacturer, official labeling requires these excipients to be listed, so patients with known intolerances to substances like lactose or specific sugars can verify the specific product's ingredients.


Q: Why are regular blood tests sometimes required when taking Flucofarma for a long time?

Official regulatory warnings describe the need for monitoring of liver function during long-term use. This is because the warnings cite a documented risk of serious liver problems, including hepatic failure, associated with fluconazole.


Q: What are the signs of a serious allergic reaction to Flucofarma?

Signs of a serious allergic reaction may include shortness of breath, wheezing, difficulty breathing, and swelling of the face, lips, tongue, or other parts of the body. These symptoms would occur in addition to rash, itching, or hives.


Q: Is Flucofarma the same medication as the drug known by the brand name Diflucan?

Flucofarma contains the active ingredient fluconazole. The product known by the brand name Diflucan also contains fluconazole and is a recognized trade name for this active substance.


Q: What happens if the fungus strain is resistant to Flucofarma?

If a fungus strain develops resistance, the capacity of the drug to maintain its inhibitory effect on the fungal cell may be reduced. Official reports acknowledge the presence of both inherent and acquired resistance for some species of fungus.


Q: Does Flucofarma contain any ingredients that could be an issue for people with celiac disease?

The labels for the various dosage forms list all inactive ingredients (excipients). Since the presence of gluten or other specific allergens is not universally confirmed or denied on the public label, official labeling requires these excipients to be listed, so the specific inactive ingredients can be verified.


Q: Do the side effects of Flucofarma vary based on the dose or strength taken?

Official warnings and safety constraints are sometimes described as being dose-dependent. For example, specific interactions are only contraindicated when fluconazole is received at multiple doses of 400 mg per day or higher, which indicates that the risk profile can vary based on the strength.


Q: What is the difference between prescription and over-the-counter uses of Flucofarma?

Official regulatory status confirms that fluconazole is a prescription-only medication in the United States. It is not available over the counter (OTC) for any of its approved uses.


Q: Why do some product labels mention avoiding Flucofarma if trying to conceive?

Official information generally establishes the requirement for using effective birth control during treatment with fluconazole. This is because high-dose and/or long-term use during pregnancy is associated with a risk of birth defects, and some studies have suggested a possible link between use during early pregnancy and an increased chance for miscarriage.


How should Flucofarma be stored and disposed of?

How to Store and Dispose of Flucofarma

Official regulatory guidelines mandate specific storage and disposal procedures for fluconazole to maintain product quality and ensure safety.

Storage Requirements

Dosage Form Required Storage Condition Stability/Handling Rules
Tablets / Dry Powder Store below 30 C (86 F) Keep in the original container, tightly closed.
Reconstituted Suspension Store between 5 C and 30 C (41 F to 86 F) Protect from freezing; discard unused portion after 2 weeks.
Intravenous Solution Store between 5 C and 25 C (41 F to 77 F) Protect from freezing and excessive heat.

All forms must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine must be disposed of properly according to official regulatory guidelines. The preferred method is using community drug take-back programs. If these are unavailable, medicines should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before being thrown in the household trash. Identifying information must be removed from the container prior to discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucofarma found in:

A-Z Index: